HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,562,868 | +17.5% | 590,651 | +10.9% | 0.02% | +23.1% |
| Q2 2023 | $19,208,284 | -9.5% | 532,528 | -4.2% | 0.01% | -13.3% |
| Q1 2023 | $21,226,918 | -45.2% | 555,824 | -18.4% | 0.02% | -48.3% |
| Q4 2022 | $38,762,216 | +81.0% | 681,234 | +25.8% | 0.03% | +70.6% |
| Q3 2022 | $21,414,000 | -23.3% | 541,579 | -14.7% | 0.02% | -19.0% |
| Q2 2022 | $27,920,000 | +42.8% | 634,560 | +29.4% | 0.02% | +75.0% |
| Q1 2022 | $19,550,000 | -1.3% | 490,218 | -0.5% | 0.01% | 0.0% |
| Q4 2021 | $19,805,000 | -9.5% | 492,521 | -8.4% | 0.01% | -14.3% |
| Q3 2021 | $21,878,000 | -5.3% | 537,812 | +5.7% | 0.01% | -6.7% |
| Q2 2021 | $23,111,000 | +13.6% | 508,947 | +4.3% | 0.02% | +7.1% |
| Q1 2021 | $20,338,000 | +10.5% | 487,823 | +13.2% | 0.01% | 0.0% |
| Q4 2020 | $18,398,000 | +1257.8% | 430,752 | +735.9% | 0.01% | +1300.0% |
| Q3 2020 | $1,355,000 | -6.7% | 51,534 | -4.9% | 0.00% | 0.0% |
| Q2 2020 | $1,452,000 | +103.6% | 54,162 | +36.6% | 0.00% | 0.0% |
| Q1 2020 | $713,000 | +1.1% | 39,641 | -0.3% | 0.00% | 0.0% |
| Q4 2019 | $705,000 | +2.5% | 39,767 | -10.3% | 0.00% | 0.0% |
| Q3 2019 | $688,000 | -0.4% | 44,344 | +10.3% | 0.00% | 0.0% |
| Q2 2019 | $691,000 | -51.9% | 40,195 | -55.0% | 0.00% | 0.0% |
| Q1 2019 | $1,437,000 | +12.3% | 89,288 | +2.0% | 0.00% | 0.0% |
| Q4 2018 | $1,280,000 | -19.3% | 87,537 | +0.2% | 0.00% | 0.0% |
| Q3 2018 | $1,587,000 | +16.9% | 87,321 | +8.6% | 0.00% | 0.0% |
| Q2 2018 | $1,357,000 | +65.1% | 80,430 | +91.7% | 0.00% | 0.0% |
| Q1 2018 | $822,000 | -3.0% | 41,951 | +0.4% | 0.00% | 0.0% |
| Q4 2017 | $847,000 | +188.1% | 41,785 | +146.7% | 0.00% | – |
| Q3 2017 | $294,000 | +14.8% | 16,941 | -15.2% | 0.00% | – |
| Q2 2017 | $256,000 | -4.1% | 19,982 | -3.0% | 0.00% | – |
| Q1 2017 | $267,000 | +34.8% | 20,602 | +2.8% | 0.00% | – |
| Q4 2016 | $198,000 | -15.4% | 20,044 | +3.3% | 0.00% | – |
| Q3 2016 | $234,000 | +41.0% | 19,404 | +1.1% | 0.00% | – |
| Q2 2016 | $166,000 | -6.2% | 19,188 | +2.6% | 0.00% | – |
| Q1 2016 | $177,000 | -44.2% | 18,696 | +2.1% | 0.00% | – |
| Q4 2015 | $317,000 | +31.5% | 18,315 | +2.1% | 0.00% | – |
| Q3 2015 | $241,000 | -41.6% | 17,945 | -1.9% | 0.00% | -100.0% |
| Q2 2015 | $413,000 | +70.7% | 18,286 | +7.6% | 0.00% | – |
| Q1 2015 | $242,000 | +45.8% | 16,990 | -1.2% | 0.00% | – |
| Q4 2014 | $166,000 | -10.8% | 17,202 | -15.7% | 0.00% | – |
| Q3 2014 | $186,000 | -7.0% | 20,398 | +0.7% | 0.00% | – |
| Q2 2014 | $200,000 | -43.8% | 20,262 | -27.7% | 0.00% | -100.0% |
| Q1 2014 | $356,000 | -3.5% | 28,028 | +13.8% | 0.00% | 0.0% |
| Q4 2013 | $369,000 | +35.7% | 24,621 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $272,000 | +23.6% | 24,621 | -11.2% | 0.00% | – |
| Q2 2013 | $220,000 | – | 27,719 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |